Industry

DUBLIN–(BUSINESS WIRE)–The “Non-Invasive Aesthetic Treatment Market Analysis by Procedure, by End use, and by Region – Global Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The non-invasive aesthetic treatment market size is estimated to be USD 55.3 billion in 2021 and is expected to witness a CAGR of 17.25% during the forecast period … [Read more…]

Revenue optimization and compliance leader delivers market-ready tools to support shifting priorities for life sciences and high-tech companies SAN MATEO, Calif.–(BUSINESS WIRE)–#BreakingNews—Model N, Inc. (NYSE: MODN), the leader in revenue optimization and compliance, today announced its Fall 2022 product release of the Model N Revenue Cloud. This latest semi-annual update focuses on bringing innovative revenue … [Read more…]

Growing demand for mental health support inspired Frankly to expand access to its mental wellness services for adults across the U.S. NEW YORK–(BUSINESS WIRE)–#mentalwellness—Frankly, the online holistic mental wellness provider, today announced the expansion of its mental wellness coaching services for adults in all 50 states to provide the right mix of tools and treatments … [Read more…]

One of the nation’s top health systems dedicated to innovation across the continuum of care, Ascension aims to drive a more patient-centric culture PROVO, Utah & SEATTLE–(BUSINESS WIRE)–Qualtrics (Nasdaq: XM), the leader and creator of the experience management category, today announced that Ascension has selected Qualtrics’ patient experience solutions to help transform how the national … [Read more…]

LONDON–(BUSINESS WIRE)–Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life and health reinsurer, is partnering with The University of Leicester, U.K., to study and quantify how multiple rating factors and comorbidities affect one another, enabling the international scientific community to better understand a range of common and life-threatening diseases. This research, sponsored by … [Read more…]

DALLAS–(BUSINESS WIRE)–Tenet Healthcare Corporation (NYSE: THC) is scheduled to present at the BofA Securities 2022 Leveraged Finance Conference on Tuesday, November 29, 2022, beginning at 8:10 a.m. Eastern time. A live webcast and audio archive of the event may be accessed through the investor relations section of Tenet’s website at www.tenethealth.com/investors. The replay will be … [Read more…]

Accident Advisor from TNEDICCA to help Ohio Mutual Insurance Group customers stay safer on the road by avoiding or using extra caution in high-risk areas COLUMBUS, Ohio & BUCYRUS, Ohio–(BUSINESS WIRE)–#AccidentAdvisor—TNEDICCA®, a leader in traffic crash data and location risk analytics, and Ohio Mutual Insurance Group are collaborating to provide a unique view into crash … [Read more…]

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today announced that the Company presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003 at Neuroscience 2022 hosted by the Society for Neuroscience (“SFN”) taking place November 12-16, 2022, in San Diego, … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary Hornby, will participate in a presentation and fireside chat at upcoming investor conferences: Piper Sandler 34th Annual Healthcare Conference Format: Presentation Date: Tuesday, November 29, 2022 … [Read more…]

Novel anticancer agent may enhance overall therapeutic efficacy of current immune checkpoint inhibitor-based treatments CHICAGO–(BUSINESS WIRE)–MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the results of a pre-clinical study of the Company’s lead drug candidate, THIO, in hepatocellular carcinoma (HCC) in vitro and … [Read more…]